Stay updated on Nivolumab in Refractory Biliary Tract Cancers Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The record now displays details for the nivolumab study in advanced refractory biliary tract cancer, including eligibility criteria, study design, treatment, outcomes, locations, and record history.
    Difference
    47%
    Check dated 2026-11-10T06:53:28.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T06:17:23.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.
    Difference
    1%
    Check dated 2026-10-27T06:45:16.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The study record remains unavailable with a 403 Forbidden error. The footer’s site revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-20T07:00:29.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-13T08:22:42.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error, replacing the detailed trial content. Added 403-related markup and basic navigation text while several study-related references were removed.
    Difference
    18%
    Check dated 2026-09-22T06:41:32.000Z thumbnail image

Stay in the know with updates to Nivolumab in Refractory Biliary Tract Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page.